Novacap strenghens its cosmetics and healthcare offering with ID bio acquisition
Novacap welcomes ID bio and H2B
Novacap, a worldwide player in the pharmaceutical and cosmetics industry, announced that it has acquired ID bio, a producer of natural ingredients for cosmetics, along with H2B, a manufacturer of fractionated blood products for in vitro diagnosis.
Novacap serves the cosmetics industry with essential ingredients used as preservatives, UV filters, exfoliants and fragrances. ID bio leverages its expertise in enzymatic extraction and purification to develop innovative active ingredients and botanical extracts. ID bio focuses on ethical and eco-friendly sourcing of raw materials to offer differentiated ingredients with controlled traceability.
Enrich Novacap’s offering
Moreover, the acquisition of ID bio by Novacap meets the group’s growth strategy which aims at supplying its clients with a wide range of active and functional ingredients and widening its cosmetic portfolio with natural products.
In addition, H2B will strengthen Novacap’s positioning on the Pharmaceutical and Healthcare markets.
ID bio and H2B’s innovation capabilities will enrich Novacap’s offering and ability to meet the needs of our customers
“Novacap will support ID bio and H2B to accelerate their development leveraging the two companies’ market approaches and recognised expertise. The complementarities between our two groups open up outstanding prospects for the future”, said Jean-Pierre Picot, Founding President of ID bio.
ID bio and H2B will benefit from Novacap’s industrial and regulatory expertise and large client portfolio to accelerate their growth.